Executive summary: U.S. Patent No. 10,912,751 protects a narrow therapeutic method using a fixed-dose combination of 180 mg bempedoic acid and 10 mg ezetimibe to treat familial hypercholesterolemia. The patent does not broadly claim bempedoic acid, ezetimibe, all bempedoic acid/ezetimibe combinations, or the tablet formulation as a composition. Its principal commercial relevance is Nexlizet, Esperion Therapeutics' fixed-dose product. The listed patent expiration date is March 27, 2037, subject to any applicable patent-term adjustment or regulatory extension shown in the FDA Orange Book.[1][2]
U.S. Patent 10,912,751: Claims, Scope, Expiration, Orange Book Status, and Generic Risk
What drug does U.S. Patent 10,912,751 protect?
U.S. Patent No. 10,912,751 covers a method of treating familial hypercholesterolemia with a fixed-dose combination of:
| Component |
Amount |
Chemical identity |
| Bempedoic acid |
180 mg |
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid |
| Ezetimibe |
10 mg |
Ezetimibe |
| Dosing |
Once daily |
As specified in dependent claims |
| Route |
Oral |
As specified in claim 11 |
| Dosage form |
Tablet |
As specified in claim 10 |
The claims correspond to the active ingredients and strengths used in Nexlizet, which is approved by the FDA as a fixed-dose combination of bempedoic acid and ezetimibe.[2][3]
The patent is assigned to Esperion Therapeutics, Inc. Patent No. 10,912,751 issued on February 9, 2021, from an application claiming priority to an earlier filing. The patent's listed expiration date is March 27, 2037.[1][2]
What is the scope of independent claim 1?
Claim 1 requires all of the following elements:
- A method of treating familial hypercholesterolemia.
- A subject in need of treatment.
- Administration of a fixed-dose combination.
- The fixed-dose combination must contain 180 mg of bempedoic acid.
- The same fixed-dose combination must contain 10 mg of ezetimibe.
The claim is a method-of-treatment claim, not a composition claim. It is directed to conduct involving administration to a patient. The claim does not independently require:
- Once-daily administration;
- Oral administration;
- A tablet;
- A specific LDL-C reduction;
- A specific hsCRP reduction;
- Statin co-administration;
- A particular age, sex, genotype, or disease severity; or
- A specific manufacturing process.
The phrase "fixed-dose combination" is important. A regimen in which a patient separately receives 180 mg of bempedoic acid and 10 mg of ezetimibe may not satisfy the fixed-dose combination limitation if the two ingredients are not supplied as a fixed-dose product. Whether a particular separate-pill regimen infringes would depend on claim construction and the evidence concerning the product and method of use.
How do claims 2 through 13 narrow the patent?
The dependent claims add therapeutic outcomes, administration conditions, and patient characteristics.
| Claim |
Added limitation |
Practical effect |
| 2 |
LDL-C lower than placebo control |
Requires comparative LDL-C efficacy |
| 3 |
Decreased hsCRP |
Adds an anti-inflammatory biomarker result |
| 4 |
Decreased very-low-density lipoprotein |
Adds a VLDL outcome |
| 5 |
Reduced cardiovascular-disease risk |
Adds a clinical-risk outcome |
| 6 |
LDL-C reduction of at least 30% from baseline |
Adds a quantitative LDL-C threshold |
| 7 |
hsCRP reduction of at least 26% from baseline |
Adds a quantitative hsCRP threshold |
| 8 |
hsCRP reduction of at least 30% from baseline |
Adds a higher quantitative hsCRP threshold |
| 9 |
Once-daily administration |
Adds dosing frequency |
| 10 |
Tablet formulation |
Adds dosage form |
| 11 |
Oral delivery |
Adds route |
| 12 |
Formulated for once-daily administration |
Adds formulation-use condition |
| 13 |
Human subject |
Limits the subject to humans |
Claims 9 and 12 overlap substantially but are not identical. Claim 9 focuses on administering the combination once daily. Claim 12 focuses on formulation for once-daily administration.
Claims 7 and 8 are nested quantitative alternatives. A treatment reducing hsCRP by at least 30% would also satisfy the at-least-26% threshold in claim 7, assuming the other limitations are met.
Does the patent claim Nexlizet as a product?
No. The patent claims a method of treating familial hypercholesterolemia using the specified combination. It does not claim:
- Nexlizet by brand name;
- A composition comprising any amount of bempedoic acid and ezetimibe;
- All fixed-dose bempedoic acid/ezetimibe products;
- The inactive ingredients or excipient system;
- Tablet hardness, dissolution, particle size, or coating;
- A manufacturing process; or
- A packaging configuration.
The patent can still create commercial barriers for a generic fixed-dose combination. A generic manufacturer could face infringement risk if its product is labeled or marketed for the patented familial-hypercholesterolemia method.
What FDA product is associated with the patent?
Nexlizet is the principal FDA-approved product associated with the claimed combination. The FDA approved Nexlizet tablets containing 180 mg bempedoic acid and 10 mg ezetimibe in March 2020.[3]
The FDA-approved product is indicated as an adjunct to diet and statin therapy, or as an alternative in patients unable to take a statin, for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia.[3]
The patent's claim language is narrower than the complete Nexlizet label because the patent focuses on familial hypercholesterolemia, while the commercial label also covers broader primary hyperlipidemia use.
What is the Orange Book status of U.S. Patent 10,912,751?
The FDA Orange Book lists U.S. Patent No. 10,912,751 in connection with Nexlizet.[2] The listing gives the patent importance in an ANDA certification proceeding because a generic applicant must address the listed patent under the Hatch-Waxman framework.
The practical Orange Book consequences are:
| Issue |
Impact |
| Listed drug |
Nexlizet |
| Listed patent type |
Method-of-use patent |
| Core protected use |
Familial hypercholesterolemia treatment |
| Commercial product |
Bempedoic acid/ezetimibe fixed-dose tablet |
| Listed expiration |
March 27, 2037 |
| Generic pathway |
ANDA with patent certification |
| Possible label strategy |
Paragraph IV challenge or section viii carve-out |
The precise legal effect depends on the patent-use code and the generic applicant's proposed label. A patent listing does not itself establish infringement or validity.
When does U.S. Patent 10,912,751 lose exclusivity?
The listed patent expiration date is March 27, 2037.[2] The relevant exclusivity timeline is:
| Event |
Date |
| Earliest priority date reflected in the patent family |
March 27, 2017 |
| Patent grant |
February 9, 2021 |
| Listed patent expiration |
March 27, 2037 |
| Earliest ordinary post-expiration generic entry |
After patent and regulatory barriers are cleared |
The effective generic-entry date could be earlier if a Paragraph IV challenger prevails in litigation or obtains a settlement-based launch right. It could also be delayed by other Orange Book-listed patents, regulatory exclusivity, injunctions, or a separate patent-term adjustment.
The patent does not appear to be a biologic patent. It therefore does not create biosimilar exclusivity under the Biologics Price Competition and Innovation Act.
What Paragraph IV challenges could target the patent?
An ANDA applicant seeking approval for a generic bempedoic acid/ezetimibe fixed-dose product could file:
- A Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed; or
- A section viii statement carving out the patented familial-hypercholesterolemia use from the proposed label.
A Paragraph IV notice would permit the patent holder to bring an infringement action under 35 U.S.C. §271(e)(2). A timely patent suit generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court action.[4]
Paragraph IV theories
Potential attack points include:
- Lack of written description for the precise 180 mg/10 mg combination;
- Lack of enablement across the full familial-hypercholesterolemia patient population;
- Obviousness based on known bempedoic acid, ezetimibe, and combination lipid-lowering therapy;
- Inherency or anticipation based on earlier clinical disclosures;
- Indefiniteness involving "fixed-dose combination," "decreases," or cardiovascular-risk reduction;
- Noninfringement based on a proposed label that omits familial hypercholesterolemia; and
- Lack of direct infringement where the product is not administered as claimed.
The strongest commercial defense may be a label carve-out if the generic applicant can remove the patented familial-hypercholesterolemia indication while retaining approval for non-patented primary-hyperlipidemia uses. That strategy becomes less effective if the proposed label, promotional materials, or actual instructions encourage the patented use.
How strong is the patent estate for bempedoic acid and ezetimibe?
Patent No. 10,912,751 is important but narrow. Its strength is highest against a generic that seeks a label expressly covering familial hypercholesterolemia and uses the exact 180 mg/10 mg fixed-dose combination.
Its strength is lower against:
- Separate-pill regimens;
- Products with different strengths;
- Products labeled only for non-familial primary hyperlipidemia;
- Products that avoid once-daily or oral-use language where those limitations matter;
- Manufacturing or formulation activities not involving patient administration; and
- Non-infringing products that do not contain both active ingredients in a fixed-dose unit.
Other bempedoic acid patents may protect the active ingredient, intermediates, compositions, or manufacturing processes. Those rights must be analyzed separately from the 751 patent. The 751 patent should not be treated as the entire Nexlizet estate.
Formulation protection
Claims 10 through 12 provide limited dosage-form and administration coverage. They do not recite excipients, release profiles, tablet dimensions, coating systems, or dissolution specifications.
A separate formulation patent could create additional barriers if it claims a particular tablet composition or manufacturing process. Conversely, a generic tablet that uses different excipients would not avoid the 751 patent if it still satisfies the method-of-treatment limitations and is administered for the claimed use.
Manufacturing and supply-chain barriers
The 751 patent does not principally protect manufacturing. A generic manufacturer may therefore need to clear separate rights involving:
- Bempedoic acid synthesis;
- Ezetimibe synthesis;
- Chiral intermediates;
- Crystallization or polymorph control;
- Tablet compression and coating;
- Stability systems; and
- Commercial-scale batch processes.
The absence of a manufacturing claim in the 751 patent does not eliminate process-patent risk.
What litigation and settlement issues affect the patent?
The patent itself does not establish a final infringement judgment, invalidity judgment, or settlement. Its litigation exposure will arise primarily when an ANDA applicant provides a Paragraph IV notice.
Potential litigation questions include:
| Issue |
Commercial significance |
| Claim construction |
Determines whether the proposed product and use satisfy fixed-dose and FH limitations |
| Written description |
Tests support for the specific combination and dosing regimen |
| Obviousness |
Examines the predictability of combining bempedoic acid with ezetimibe |
| Label carve-out |
Determines whether an ANDA can avoid the patented use |
| Induced infringement |
Focuses on generic labeling and marketing conduct |
| Injunction or stay |
Can delay commercial approval or launch |
| Settlement |
May establish a negotiated launch date before 2037 |
A settlement could permit an authorized generic or an agreed future launch date without a final merits decision. The existence of a settlement would not by itself establish patent validity.
How does the patent compare with competing lipid-lowering products?
| Product |
Active ingredient or combination |
Patent type relevant to competition |
Biosimilar risk |
| Nexlizet |
Bempedoic acid 180 mg + ezetimibe 10 mg |
Combination and method-of-use patents |
None |
| Nexletol |
Bempedoic acid 180 mg |
Active-ingredient, formulation, and method patents in the broader estate |
None |
| Ezetimibe generics |
Ezetimibe |
Earlier compound and product patents largely expired |
None |
| PCSK9 monoclonal antibodies |
Evolocumab or alirocumab |
Biologic patents and regulatory exclusivity |
Biosimilar risk applies |
| Inclisiran |
Inclisiran |
Oligonucleotide and formulation patents |
Biosimilar pathway generally not applicable |
Nexlizet competes with statins, ezetimibe monotherapy, bempedoic acid monotherapy, PCSK9 inhibitors, and inclisiran. The 751 patent is specific to the bempedoic acid/ezetimibe combination and does not prevent competition from those alternatives.
What generic launch scenarios exist?
Scenario 1: No challenge before expiration
A generic applicant waits for the listed patent to expire and seeks approval without litigating the patent. Launch would occur after regulatory approval and clearance of any other blocking rights.
Scenario 2: Paragraph IV litigation
The applicant certifies the patent as invalid, unenforceable, or not infringed. Esperion files suit, potentially triggering the statutory approval stay. The outcome could be an early launch, an injunction, or a negotiated settlement.
Scenario 3: Section viii carve-out
The applicant removes familial hypercholesterolemia from its label and seeks approval for non-patented indications. This is the most direct route around a method-of-use patent, but it carries risk if the remaining label or marketing encourages the patented use.
Scenario 4: Alternative strength or separate-pill product
A product that does not contain the fixed 180 mg/10 mg combination may avoid literal infringement of claim 1. It could still face other patents and regulatory limitations.
What geographic coverage does the patent provide?
U.S. Patent No. 10,912,751 provides rights only in the United States. It does not directly block generic or combination-product activity in Europe, Canada, Japan, or other markets.
Foreign counterparts must be reviewed individually for:
- Granted claims;
- Patent term;
- Supplementary protection certificates;
- Local patent litigation;
- National claim amendments; and
- Regulatory-use protection.
A U.S. Orange Book listing has no direct legal effect outside the United States.
What is the revenue exposure from this patent?
The patent's direct revenue exposure is Nexlizet revenue associated with the familial-hypercholesterolemia segment and with other prescribing behavior that may be affected by a generic fixed-dose combination.
The patent does not independently protect all Esperion revenue because:
- Nexletol is a separate bempedoic acid product;
- Non-combination products may rely on different patent families;
- The patent does not cover ezetimibe generally; and
- A generic may initially enter with a carved-out label.
The economic value of the patent therefore depends on whether a generic can obtain approval for broad primary-hyperlipidemia use without retaining the patented familial-hypercholesterolemia indication.
Key takeaways
- U.S. Patent No. 10,912,751 is a narrow method-of-treatment patent.
- Claim 1 requires 180 mg bempedoic acid plus 10 mg ezetimibe in a fixed-dose combination.
- The principal commercial product is Nexlizet.
- The listed patent expiration date is March 27, 2037.
- The patent does not broadly claim bempedoic acid, ezetimibe, or every combination of the two.
- Tablet, oral, and once-daily limitations appear only in dependent claims.
- A generic may consider Paragraph IV litigation or a section viii label carve-out.
- The patent is not a biologic patent and does not create biosimilar exclusivity.
- Separate formulation, process, active-ingredient, and manufacturing patents may materially affect generic entry.
- U.S. rights do not establish blocking rights in foreign jurisdictions.
FAQs about U.S. Patent 10,912,751
Does the patent cover bempedoic acid monotherapy?
No. The claims require both bempedoic acid and ezetimibe in the specified fixed-dose combination.
Does a 180 mg bempedoic acid tablet plus a separate 10 mg ezetimibe tablet infringe?
Not necessarily. Claim 1 requires a fixed-dose combination. Separate products may avoid literal infringement, although other patents or infringement theories could apply.
Can a generic launch with the familial hypercholesterolemia indication removed?
Potentially. A section viii carve-out may be available if the remaining label does not include or promote the patented use. The generic must still address other listed patents and regulatory requirements.
Is the patent limited to patients receiving statins?
The supplied claims do not require statin co-administration. The FDA product label contains statin-related treatment language, but the patent claims should be analyzed separately from the approved label.
Does the patent cover cardiovascular-risk reduction?
Claim 5 recites reduced cardiovascular-disease risk as a dependent method limitation. The claim does not automatically cover every use of the combination unless the other claim 1 limitations are also met.
References
- United States Patent and Trademark Office. (2021). U.S. Patent No. 10,912,751, methods of treating familial hypercholesterolemia.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Nexlizet (bempedoic acid and ezetimibe) prescribing information.
- Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
